Clinical study of favipiravir for patients with severe fever with thrombocytopenia syndrome 2017

Not Applicable

• Conditions: severe fever with thrombocytopenia syndrome

• Registration Number: JPRN-UMIN000029020
• Lead Sponsor: Ehime University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-11
• Study Completion: 2019-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who are revealed of SFTSV load decreasing or had improvements of clinical manifestation 2. Patients who had been running fever while seven or more days 3. Patients who are treated for severe hepatic disease (Child-Pugh grade C) 4. Pregnant women or patients who might be pregnant 5. Patients who have difficulty in taking the extremely effective contraception during the first day of treatment with favipiravir until 7days after the medication 6. Patients who suffer from hereditary xanthinuria 7. Patients who have hypouriceia (less than 1mg/dl) or had been made a diagnosis of urinary tract xanthine calculus 8. Patients who have a history of hyper sensitivity for favipiravir 9. Patients who are inadequate for enrollment for this protocol with the investigator's judgment

Study & Design

• Study Type: Interventional
• Study Design: Not specified